

ICBP Clinical Committees

ICBP CLINICAL ADVISOR JOHN BUTLER

LUNG	UPPER GI	LOWER GI	LIVER & PANCREAS	OVARIAN	PRIMARY CARE	DIAGNOSTICS & PATHOLOGY
Christian Finley (Lead)	Piers Gatenby (Lead)	Allan Spigelman (Lead)		John Butler (Lead)	Fiona Walter (Lead)	
Karl Kölbeck	Christian Finley	Annika Sjövall	Neil Merrett	Neville Hacker	Bridget Gwynne	Mark Robinson
Jason Lester	Wyn Lewis	Jason Park	David Ransom	Andy Nordin	Peter Vedsted	Robert Bleeheh
Brian McCaughan	Neil Merrett	Marcia Hall	Elijah Dixon	Scott Fegan	Hans Thulesius	Patrick Fielding
David Baldwin	Alan Christie	Geoff Porter	Alan Christie	Marcia Hall	Brian Nicholson	Paulose George
Ian Williamson	David Ransom	Marianne Grønlie Guren	Keith Roberts	Michael Fung-Kee-Fung	Georgios (Yoryos) Lyrtzopoulos	Kate Gower-Thomas
Erik Jakobsen	Geoff Porter	Nancy Baxter	Nagappan Kumar	Iain McNeish	Susanna Hill	Michael Eden
Mick Peake	John Zalberg	Christopher Booth	Geoff Porter	Jason Tan	Richard Roope	Maurice Loughrey
Wendy Anderson	Natalie Coburn	David Ransom	Natalie Coburn	Louise Hanna	Richard Neal	
Jonathan McAleese	Paulose George	Winson Cheung		Gunnar Kristensen	Jon Emery	
	Tom Crosby	Ashley Roberts		Johnny Price	David Weller	
		Rachel Hargest			Clifford Jones	
		Richard Adams			Anant Jani	
		Maurice Loughrey			Ken O'Neill	
		Roy Maxwell			Nigel Hart	
					Ross Lawrenson	

To read about all of our ICBP clinicians please scroll down, or click on a name to be taken to their biography.

Name	Biography
Alan Christie <i>Scotland</i>	Dr Alan Christie MBChB, MSc. is a consultant medical oncologist with a specialist interest in upper GI, HPB and skin cancers, working at the Edinburgh Cancer Centre, UK. He graduated from Aberdeen University, UK, in 2005 and worked as a junior doctor in Aberdeen, New Zealand and Glasgow before completing his specialist training in medical oncology in Edinburgh. He received an MSc in Translational Medicine from the University of Edinburgh in 2015.
Allan Spigelman <i>Australia</i>	Allan Spigelman is Professor of Surgery, UNSW St Vincent's Hospital Clinical School, Sydney, Australia. He is also Director St Vincent's Cancer Genetics Service and the Hunter Family Cancer Service, NSW, Australia. He has Clinical Associate Dean for 9 years. He co-ordinated Australia's first national colorectal cancer survey, was the first Director of Clinical Governance appointed in Australia and is Regional Editor of the International Journal of Health Governance. He was Director of Cancer Services for two Area Health Services. He is a member of the NSW Medical Board and sits on the NSW Confidential Audit of Surgical Mortality Committee of the Clinical Excellence Commission and RACS in NSW. His research interests and publications span the fields of patient safety and clinical quality, audit, outcomes, education, surgery, surgical oncology and cancer genetics. The international staging system for duodenal polyposis in Familial Adenomatous Polyposis, a high cancer risk syndrome (particularly for colorectal cancer) bears his name.
Anant Jani <i>England</i>	Anant Jani, PhD, Honorary Research Fellow. Anant's experience in health care started when working with Sir Muir Gray on the QIPP Right Care programme in the England Department of Health. This involved helping localities across England to design and implement high value population-based healthcare systems, including building the first national system for stroke prevention for patients with Atrial Fibrillation, which was a joint venture with NHS England and Public Health England. Anant is working on the value based healthcare theme within the Nuffield Department of Primary Care Health Sciences and is interested in understanding and implementing value based healthcare, particularly focusing on the Triple Value framework: <ul style="list-style-type: none"> • Allocative value, determined by how the assets are distributed to different sub groups in the population • Technical value, determined by how well resources are used for all the people in need in each sub group • Personal value, determined by how well the decision relates to the values of each individual Before working in healthcare, Anant was a molecular immunologist studying gene regulation and epigenetics in B and T cells. He completed his undergraduate studies at Brandeis University and his doctoral studies at Yale University. See publications here: https://uk.linkedin.com/pub/anant-jani/4a/545/a38
Andy Nordin <i>England</i>	Dr Andy Nordin was appointed consultant gynaecological oncologist at the East Kent Gynaecological Oncology Centre in 2000, following subspecialty training in Gateshead. He has held honorary senior lectureship contracts at the University of Kent at Canterbury and University College London. Andy took up post as the President of the British Gynaecological Cancer Society in May 2016. Until recently Andy chaired the National Cancer Intelligence Network Gynaecology Clinical Reference Group, the national Gynaecology Network Leads Group and the BGCS Commissioning Subgroup. He was the national clinical lead for gynaecology the Cancer Services Collaborative and NHS Improvement, and served as a clinical lead for England in the International Cancer Benchmarking Partnership. Andy is an active member of the EORTC Quality of Life and Gynecologic Cancer groups, and sits on a number of trial management, trial steering committee and data monitoring committees for national and international trials.
Annika Sjövall <i>Sweden</i>	Annika Sjövall is a colorectal surgeon at Karolinska University Hospital in Stockholm, Sweden. She is focused on colorectal cancer management; by surgery, by projects of improving care pathways, as author of national and regional guidelines and as author of large amounts of patient information. She is chairman of the Stockholm Colorectal Cancer Study group since 2008 and responsible for the launching of the Standardised Care Pathway for patients with colorectal cancer in the Stockholm-Gotland region. Her Ph.D. "Colon Cancer – Management and outcome in a Swedish population" was published in 2007 at Karolinska Institutet in Stockholm and her research has continued to focus on colorectal cancer. She has also introduced patient reported experience measures and patient reported outcome measures for all patients who have undergone abdominal resection for colorectal cancer in Stockholm-Gotland since 2013 and in the whole country of Sweden since 2015.
Ashley Roberts <i>Wales</i>	
Brian McCaughan <i>Australia</i>	Prof Brian McCaughan is a renowned cardiothoracic surgeon with a career long commitment and passion for the management of thoracic malignancies. He is also Chairman of the Clinical Excellence Commission and the Agency for Clinical Innovation. A Clinical Associate Professor at the University of Sydney, Brian has had a clinical career of 40 years at Royal Prince Alfred Hospital and Concord Hospital.

	<p>He was also involved in many management roles at hospital, district, state and commonwealth level. These included the RPA Director of Surgery, Central Sydney Area Director of Cardiovascular Service and he was elected the Chairman of the New South Wales State Committee of the Royal Australasian College of Surgeons. Prof McCaughan was appointed to the New South Wales Health Council and served as the President of the New South Wales Medical Board from 1999 to 2004. He was Chair of the Sustainable Access Task Force and also a member of the Health Minister’s Advisory Council for New South Wales Health. In 2009 he was awarded Member of the Order of Australia for his services to medicine.</p>
<p>Brian Nicholson <i>England</i></p>	<p>Brian is a General Practitioner and clinical researcher based at the Nuffield Department of Primary Care Health Sciences at the University of Oxford, UK. His research interests centre around diagnosis and cancer in primary care populations. He has received funding from the NIHR, NIHR School for Primary Care Research, and Cancer Research UK. As the Macmillan GP Facilitator for Oxfordshire he is working on the regions Accelerate Coordinate Evaluate (ACE) wave 2 Multi-Disciplinary Centre (MDC) pilot for non-specific symptoms of cancer. For further information: http://www.phc.ox.ac.uk/team/brian-nicholson</p>
<p>Bridget Gwynne <i>Wales</i></p>	<p>I have been a GP in Llanelli since 1989. An interest in Palliative care lead me initially work with Macmillan as an end of life facilitator in Carmarthenshire. Since 2010 I have been a Macmillan GP Adviser (GPA) for Wales. In my GPA role I have worked on the development of the Macmillan computerised Risk assessment tools to support earlier diagnosis of cancer in General Practice. In Wales I have helped develop the recently launched Framework for cancer in primary care in Wales programme.</p>
<p>Christopher Booth <i>Canada</i></p>	<p>Christopher Booth MD FRCPC is a Medical Oncologist and Health Services Researcher at Queen’s University in Kingston, Canada. He is an Associate Professor of Oncology and holds the Canada Research Chair in Population Cancer Care. Dr. Booth studied medicine at Queen’s University and did postgraduate training in Internal Medicine and Medical Oncology at the University of Toronto. Upon completing his clinical training he spent two years as a research fellow with the NCIC Clinical Trials Group at Queen’s University Cancer Research Institute. In his clinical practice he provides care to patients with gastrointestinal and genitourinary cancers. Dr. Booth has an active program in population-based cancer research which is supported by operating grants from the Canadian Institutes of Health Research, Canadian Cancer Society, and Canada Foundation for Innovation. As a junior investigator he was awarded an inaugural Cancer Care Ontario Chair in Health Services Research. Dr. Booth has published over 100 peer-reviewed manuscripts. The focus of his research program is to evaluate the effectiveness of new therapies in the general population and the quality of care delivered to patients in routine clinical practice. In 2016 he spent a sabbatical as a visiting scientist at the Regional Cancer Centre in Trivandrum, India to develop a collaborative program in health services research.</p>
<p>Christian Finley <i>Canada</i></p>	<p>Dr. Christian Finley trained in General Surgery at University of British Columbia in Vancouver, BC and thereafter completed his training in Thoracic Surgery at the University of Toronto. He completed his Masters of Public Health at Harvard University. After completing advanced training in Leuven, Belgium and England, he started working at St. Joseph's Healthcare Hamilton in 2010. He is currently appointed as an Associate Professor in the Department of Surgery, McMaster University. Since joining the Division of Thoracic Surgery, Dr. Finley has been awarded more than \$3,000,000 in research funding for his active research program focused on thoracic surgery surgical outcomes and has put considerable effort towards developing the collaborative clinical research program with his Thoracic Surgery colleagues. Dr. Finley is also the Research Chair for the Canadian Association of Thoracic Surgeons, where he has the opportunity to lead quality improvement projects on a national scale and encourage multi-institutional collaborations. He is the proud father of three wonderful girls.</p>
<p>Clifford Jones <i>Wales</i></p>	<p>Dr Clifford Jones, FRCGP (2015), MRCP (2008), DRCOG (2007), MB BCH (UWCM, 2003). Dr Clifford Jones is a GP in the South Wales Valleys, a GP Trainer and Macmillan National GP Lead for the Framework for Cancer in Primary Care. He worked for 4 years as Macmillan GP Facilitator for End of Life for Aneurin Bevan University Health Board, which involved developing and delivering training for primary care and community teams on end of life care issues, developing a ‘Palliative Care Strategy’ for Gwent with the NHS and Third Sector, and improving palliative care provision in the Primary Care setting.</p> <p>He was also a member of the Wales Palliative Care Implementation Group team responsible for reviewing and replacing the Integrated Care Priorities for the Last Days of Life, following on from the Neuberger Review ‘More Care, Less Pathway’. He has recently taken on the new role of National GP Lead for the Macmillan Framework for Cancer in Primary Care. The Framework for Cancer programme aims to provide Primary Care teams with tools, guidance and educational resources to improve the level of care provided to people affected by cancer. It will also establish and develop a Primary Care led “community of practice” to champion and support service development and quality improvement at all stages of the cancer journey, across Wales. He is part of the RCGP Clinical Advisors group, contributes to peer review and consultations on research proposals and guideline development, and has been part of editorial teams for palliative care and Macmillan Cancer publications.</p> <p>Dr Jones is also the current chair of the RCGP Wales End of Life Network, and was made a fellow of the Royal College of General Practitioners in June 2015, in recognition of his contribution to end of life care service improvement and education.</p>

David Baldwin <i>England</i>	<p>David Baldwin works as a consultant respiratory physician sub-specialising in lung cancer and mesothelioma and interventional procedures. He is Chair of the Clinical Reference Group for Lung Cancer, NHS England and Lead for the East Midlands Expert Clinical Advisory Group on Lung Cancer and Mesothelioma. He is Honorary Professor in the School of Medicine at the University of Nottingham. He has obtained research grants from a variety of charities and NIHR.</p> <p>His primary research interests are in CT screening and lung cancer epidemiology. He is lead respiratory physician on the UK CT lung cancer screening trial (UKLS). He has published over 140 papers. He has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group and Chair of the Quality Standards Group on Lung Cancer. He works with Public Health England and the National Cancer Research Institute and is Chair of the Screening Prevention and Early Diagnosis Group. He enjoys time with his family and is a keen windsurfer and advanced instructor.</p>
David Ransom <i>Australia</i>	<p>David Ransom is a Medical Oncologist with 25 years' experience as a clinician. Previously he worked in both public hospital system and in private practice, but more recently he has only worked in the public system. Currently his clinical commitment is at Fiona Stanley Hospital in Perth Western Australia. His practice is focussed on gastrointestinal and neuroendocrine cancers. He has a number of publications in this area. For the last few years he has also been working in the Western Australian Department of Health with a focus on policy and planning for cancer management at a state level. He has a particular interest in equity of access and safety and quality of cancer treatment.</p>
David Weller <i>Scotland</i>	<p>David Weller graduated from the University of Adelaide in 1982, and undertook GP and public health training in the UK and Australia (including the MPH at University of Adelaide, 1989-90). After senior lecturer posts in Australia he moved to Edinburgh in 2000, where he is the James Mackenzie Professor of General Practice and Co-Director of the Centre for Population Health Sciences. He was Head of School from 2005-2012 and was Director for taught Masters programmes in the medical school from 2013-2015. He is currently International Dean for East/South East Asia and Australasia. His research is mainly in cancer prevention and management, and he leads the Cancer and Primary Care Research International Network (Ca-PRI). David sits on various Scottish and UK cancer advisory boards.</p>
Elijah Dixon <i>Canada</i>	<p>Dr. Elijah Dixon attended medical school at the University of Manitoba, and then surgical residency at the University of Calgary. From there he went to the University of Toronto and did a fellowship in Hepatobiliary/pancreatic surgery and GI transplantation at the Toronto Hospital. He then proceeded to the Harvard School of Public Health and did a Masters in Epidemiology. In 2004 he returned to the University of Calgary where he is an Associate Professor of Surgery, Oncology, and Community Health Sciences. His practice is focused on Hepatobiliary and Pancreatic Surgical Oncology. His research is focused on health services research, clinical trials, and improving the quality of cancer surgery.</p>
Erik Jakobsen <i>Denmark</i>	<p>I am a thoracic surgeon working as a chief surgeon and clinical associate professor at Odense University Hospital in Denmark. I am also head of the Danish lung cancer registry since 2000 and have participated in a number of international projects in lung cancer including the first ICBP. I am at the moment also a member of the European Respiratory Society taskforces working with lung cancer benchmarking.</p>
Fiona Walter <i>England</i>	<p>Fiona Walter is Principal Researcher in Primary Care Cancer Research at the University of Cambridge, and a steering group member of Cambridge Cancer Centre's Early Detection programme. She chairs the Early Diagnosis sub-group of the NCRI's Primary Care Clinical Studies Group (CSG) and is also a member of the NCRI's Skin Cancer, and Screening, Prevention and Early Diagnosis (SPED) groups. Fiona is Honorary Clinical Associate Professor at the University of Melbourne, Australia and the University of Western Australia. She continues to practice as a GP, and collaborates with primary care researchers across the UK, Europe and Australia. The link to her web page is http://www.phpc.cam.ac.uk/people/pcu-group/pcu-senior-academic-staff/fiona-walter/</p>
Geoff Porter <i>Canada</i>	<p>Geoffrey A. Porter, MD, MSc, FACS, FRCS. Dr. Porter is currently a Professor in the Departments of Surgery and Community Health and Epidemiology at Dalhousie University in Halifax, Nova Scotia. He holds the Gibran and Jamie Ramia Chair in Surgical Oncology Research and also serves as Director of the Cancer Outcomes Research Unit at Dalhousie. In addition, Dr. Porter is the Expert Lead, Clinical Care at the Canadian Partnership Against Cancer (CPAC), Canada's national cancer control organization. He has served in many other administrative roles, including as the Head of the Cancer Care Program in Halifax, as well as the Chair of Surgical Quality Control for the Radiation Therapy Oncology Group (RTOG). His research interests are broadly categorized as cancer health services research related with a specific focus on cancer surgery, as well as knowledge translation strategies targeting improved quality of cancer care at a population level.</p> <p>Dr. Porter began his post-secondary studies in 1986 at Queen's University, graduating with a degree in medicine in 1992. From Queen's University, Dr. Porter attended the University of Alberta where he received a Master's in Medical Sciences (epidemiology) in 1996 and completed a five-year residency in General Surgery in 1998. He came to the Department of Surgery at Dalhousie University in 2000 after completing a two-year fellowship in Surgical Oncology at the M.D. Anderson Cancer Center in Houston, Texas.</p>

Georgios (Yoryos) Lyratzopoulos <i>England</i>	<p>Georgios Lyratzopoulos (MD, FFPH, FRCP, MPH) is Cancer Research-UK Advanced Clinician Scientist Fellow (2015-19) and Reader in Cancer Epidemiology at University College London (UCL). As a cancer healthcare and outcomes epidemiologist, his chief current interests are variation in diagnostic intervals and pathways in symptomatic patients with cancer, and variations in cancer treatment and cancer patient experience. He was previously National Institute for Health Research (NIHR) Post-Doctoral Fellow (2012-14) in the University of Cambridge and has worked for the English National Health Service and the National Institute for Clinical Excellence (NICE) as a hospital doctor and public health physician. To April 2016 he has published over 120 peer-reviewed papers, 2/3s of which as first or last author. His PubMed/Medline record can be found here http://tinyurl.com/lncq7f and his profile here http://iris.ucl.ac.uk/iris/browse/profile?upi=GLYRA17</p>
Gunnar Kristensen <i>Denmark</i>	<p>I am a senior consultant with a Medical degree from University of Aarhus, Denmark (1972), passing the American ECFMG examination the same year. I received basic clinical training in Denmark, followed by specialisation in gynecology and obstetrics, becoming board certified in 1982. I worked at the University Hospital of Odense in Denmark from 1982 to 1989 with special interest in surgical gynecologic oncology, before starting work full time with gynecologic oncology at the Norwegian Radium Hospital, where I have worked since as consultant.</p> <p>In recent years I have been working on studies on how to improve the efficacy of treatment for cervical cancer and at the same time reduce the morbidity from the treatment. These efforts have to a great extent been successful as evidenced by the increasing survival figures from our institution. Presently, we are running several studies to improve the detection of tumor spread outside the cervix at time of diagnosis, to predict prognosis and to predict the risk of late radiation damage after radiation for cervical cancer. From 1998 to 2013, I was president of the Nordic Society for Gynecologic Oncology, which is a cooperative group engaged in clinical research. I am author of 235 scientific articles in peer-reviewed journals and of 30 chapters in books.</p>
Hans Thulesius <i>Sweden</i>	<p>Born 1959, work 50% as GP/family physician and 50% research/mentoring/teaching. Associate Prof at Lund University since 2011. Swedish editor of 'Scand J Prim Health Care' since 2010. Presently working with a baseline patient record audit protocol for the Swedish standardised cancer pathways project. Beginning in primary care and ending with start of treatment. I also work on comparative data from Swedish and Danish GPs respondents to the ICBP module 3 survey - the Swedish and Danish surveys had space for open ended comments for every item and I am analysing that data hoping to produce a paper.</p>
Iain McNeish <i>Scotland</i>	<p>Iain McNeish became Professor of Gynaecological Oncology at the Institute of Cancer Sciences, University of Glasgow in 2012. Previously, he trained in medicine at the University of Oxford from 1986 to 1992. After graduating, he undertook junior medical jobs in Oxford and Glasgow from 1992 until 1995. He was then an MRC Clinical Fellow at the University of Birmingham until 1998 and an ICRF/Cancer Research UK Clinician Scientist from 1999 to 2007.</p> <p>From 2007 until 2012, he was an MRC Senior Clinical Fellow at Barts Cancer Institute, London. He runs a lab that specialises in developing novel biological therapies for ovarian cancer including gene and viral therapies, as well as understanding the fundamental biology of ovarian cancer.</p> <p>Clinically, he is a consultant medical oncologist at the Beatson West of Scotland Cancer Centre. He has been a member of the NCRI Gynaecological Clinical Studies Group since 2006 and chaired the ovarian subgroup from 2009 – 2014. In April 2014, he was appointed Chair of the Gynae CSG. He also represents the UK on the Gynecologic Cancer Intergroup.</p>
Ian Williamson <i>Wales</i>	<p>Dr Ian Williamson is Assistant Medical Director for Cancer Services in Aneurin Bevan University Health Board, South Wales. He is a chest physician with an interest in the diagnosis and management of lung cancer. He has led the lung cancer service within the Heath Board for over 10 years and has chaired the Wales Lung Cancer Group since 2005. He has a particular interest in the early diagnosis and detection of lung cancer and using key clinical indicators and patient outcomes to drive improvements in pathway development. He has also worked closely with the Wales Oncology National Specialist Advisory Group to advice Welsh Government on the delivery of cancer services within Wales.</p>
Jason Park <i>Canada</i>	<p>Dr. Jason Park completed medical school and obtained a Master of Education degree at the University of Toronto. He completed his residency in General Surgery at the University of Manitoba and a Fellowship in Surgical Oncology at the renowned cancer centre Memorial Sloan-Kettering in New York City. Dr. Park is a Surgical Oncologist at St. Boniface General Hospital and CancerCare Manitoba in Winnipeg, Manitoba, Canada. He is also an Associate Professor in the Section of Surgical Oncology at the University Manitoba. His clinical focus includes surgery for complex colorectal cancers, laparoscopic colorectal surgery, and GI endoscopy. He also serves as an Associate Editor for the Canadian Journal of Surgery and Editor of the Oncology Education section for Current Oncology.</p>
Jason Lester <i>Wales</i>	<p>Dr Jason Lester is a Consultant Clinical Oncologist specialising in lung cancer and urological cancers at Velindre Cancer Centre. He is currently Deputy Clinical Director. Dr Lester is a committee member of the British Thoracic Oncology group and member of the National Lung Cancer Consortium. He is the lead investigator in the I-START trial, which is looking at dose escalated radiotherapy in non-small cell lung cancer and the SKOPOS trial, looking at a vaccine in combination with chemotherapy for malignant pleural mesothelioma. Dr Lester is the clinical director of The Stepping Stones Appeal, the Wales-based lung cancer charity.</p>

<p>Jason Tan <i>Australia</i></p>	<p>Dr Jason Tan, raised and educated in Perth, received his Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of Western Australia in 1998. Thereafter, he completed six years of specialist training in obstetrics and gynaecology and was certified Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (FRANZCOG) in 2007. He undertook further training and completed his fellowship in advanced gynaecological endoscopy at Monash Medical Centre, Melbourne, in 2008. Dr Tan trained further for three years to subspecialise in gynaecological oncology at Mercy Hospital for Women, Melbourne; Queensland Centre for Gynaecological Cancers, Brisbane; and Ariake Cancer Research Centre, Tokyo, Japan; and received his Certificate of Gynaecological Oncology (CGO) in 2010. In addition to that, he completed his fellowship in upper gastrointestinal surgery and bariatric surgery, at Sir Charles Gairdner Hospital in 2011.</p> <p>Dr Tan's special interest is surgical management of cancer, particularly in radical debulking surgery, and specialises in laparoscopic management of gynaecological cancer. He sees patients with cancers of the ovaries, fallopian tubes, cervix, uterus, vulva and vagina. Besides that, he also sees patients with benign gynaecological conditions requiring complex surgery, such as severe endometriosis, fibroids and complex pelvic masses, as well as, investigation and management of abnormal Pap smears.</p> <p>Dr Tan pioneered the robotic surgery for gynaecology and gynaecological oncology in Western Australia with the da Vinci System, further enhancing the legacy of minimally invasive surgery pioneered in Perth by the late Dr Tony McCartney. Robot assisted approach is advantageous in highly complicated procedures due to the better vision and dexterity, offered by the robotic instrumentation. Dr Tan founded WOMEN Centre, a leading multidisciplinary private centre for women's health in Western Australia, in 2014. The specialists at WOMEN Centre provide a truly collaborative approach to patient care in order to ensure the best outcome possible and patients regaining their quality of life after treatment.</p> <p>Besides his practice at WOMEN Centre, Dr Tan devotes half his time to the public health service as consultant gynaecological oncologist at King Edward Memorial Hospital, which includes the teaching and training of medical trainees and junior doctors. He is also the current lead clinician for gynaecology and gynaecological oncology for the Western Australia Cancer and Palliative Care Network and a clinical senior lecturer at University of Notre Dame and University of Western Australia, as well as, preceptor at various surgical skills development workshops.</p>
<p>John Butler <i>England</i></p>	<p>John Butler is a gynaecological surgeon. He is certified as both a specialist gynaecologist and sub-specialist gynaecological oncology by the RCOG. He qualified in medicine from St Mary's Hospital in 2000 and continued his postgraduate training in London, including his oncology training at the Royal Marsden and St Bartholomew's Hospital. He has an active research portfolio and has published extensively on gynaecological cancer, international cancer survival, and cancer policy. He is the lead clinician to the International Cancer Benchmarking Partnership, a member of the NCIN clinical reference group, and the Cancer Research UK Early diagnosis committee. His main interests include ultra-radical gynaecological cancer surgery, fertility preserving surgery for cervical cancer, minimal access surgery, risk reducing surgery for BRCA, and vulvar cancer.</p>
<p>John Zalberg <i>Australia</i></p>	<p>Professor John Zalberg was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to recently taking up the position of Professor of Cancer Research in the School of Public Health and Preventive Medicine at Monash University. After earning a Bachelor of Medicine and Bachelor of Surgery from the University of Melbourne and a PhD in cancer immunology, he served as Director of Medical Oncology at the Heidelberg Repatriation Hospital and as Director of Cancer Services at the Austin and Repatriation Medical Centre.</p> <p>A founder of the Lorne Cancer Conference and the Australasian Gastrointestinal Trials Group (AGITG), he is immediate past Chair of the Board of AGITG after serving in this role for over 15 years and a past Board Member of Cancer Trials Australia. He is the current Co-Chair of the Cancer Drugs Alliance and Chair of the Australian Clinical Trials Alliance. A past Board Member of the NSW Cancer Institute, past President of the Clinical Oncological Society of Australia, and a past Member of the Consultative Council of the Victorian Cancer Agency, he has received a Medal of the Order of Australia Award (OAM) and the 2011 Cancer Achievement Award from the Medical Oncology Group of Australia.</p> <p>Professor Zalberg's clinical research interests include gastrointestinal cancer and health care outcomes. He has published more than 250 articles in peer-reviewed journals. He was a Principal Investigator for the EORTC advanced GIST trial in Australia and continues an active involvement in trials in this disease as well as other GI cancers. He continues an active clinical practice in GI cancer.</p>
<p>Johnny Price <i>Northern Ireland</i></p>	
<p>Jon Emery <i>Australia</i></p>	<p>Prof Jon Emery is the Herman Professor of Primary Care Cancer Research at the University of Melbourne and Western Health, a new Chair developed within the Victorian Comprehensive Cancer Centre. He is an NHMRC Practitioner Fellow, Director of the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4), and a Visiting Research Fellow at the University of Cambridge. He studied medicine at Cambridge and Oxford and obtained his DPhil at Oxford on computer decision support</p>

	to assess cancer risk in general practice. His research interests are in the role of primary care in cancer prevention, diagnosis and follow-up, and primary care trials of complex interventions. He leads a parallel program of cancer research between Melbourne and Cambridge on cancer screening, early diagnosis and follow-up care. He has published over 170 papers and has been a Chief Investigator on research grants and awards totalling over \$AUD15 million and GBP11 million.
Jonathan McAleese <i>Northern Ireland</i>	
Karl Kölbeck <i>Sweden</i>	Dr Kölbeck graduated from Karolinska Institute in 1975, gaining his MD in 1979 and a PhD in 2003 from the Karolinska Institute. He is specialised in Pulmonary Diseases (1984) and Allergology (1989). He has been a Consultant at Karolinska University Hospital since 1996, and Head of Lung Oncology at Dept of Pulmonary Diseases 1996-2016. At present, he is the process leader for the Lung Cancer at Karolinska. He is also a member of the Swedish Lung Cancer Study Group. Research: More than 25 peer reviewed publications, in later years mainly in the lung cancer field.
Kate Gower-Thomas <i>Wales</i>	
Keith Roberts <i>England</i>	
Ken O'Neill <i>Scotland</i>	<p>Dr Kenneth O'Neill MB ChB BSc (Hons) MRCP. I have been a General Practitioner in Glasgow Scotland in a group practice which has a high level of deprivation since 1988. I have been a Clinical Director and Primary Care Cancer Lead within NHS Greater Glasgow & Clyde since 2006. From January 2016 I have been the Clinical Lead for the West of Scotland Primary Care Cancer Group. The key remit of this post is to provide clinical leadership for:</p> <ul style="list-style-type: none"> • The development of patient centred cancer services across the region for people affected by cancer in line with national policy, standards and clinical evidence base • The review of relevant clinical quality standards • The ongoing development, progression and review of a regional programme of work for the West of Scotland Primary Care Cancer Network. <p>Key areas of work are :</p> <ul style="list-style-type: none"> • The Detect Cancer Early campaign and the engagement of Primary Care in reducing levels of non-engagement in the Bowel Screening Programme • Incorporating performance status in electronic referrals for ' urgent suspected cancer ' cases • Use of Treatment Summaries • Maximising health promoting opportunities within Primary Care to improve outcomes.
Louise Hanna <i>Wales</i>	Dr Louise Hanna is a consultant clinical oncologist working in the Velindre Cancer Centre in Cardiff. Dr Hanna graduated from Cambridge and Oxford Universities and worked in England before undertaking her clinical oncology training in Wales. She is also currently appointed within Cardiff University as Local Faculty Lead.
Marcia Hall <i>England</i>	Dr Marcia Hall trained at Guy's Hospital Medical School, qualifying in 1986. Following training and a PhD in the Cell Cycle Laboratory at the Imperial Cancer Research Fund (now CRUK), she was appointed as a consultant medical oncologist at Mount Vernon Cancer Centre in 1999. Her main interest is the management of gynaecological malignancies, especially ovarian cancer. Keeping as many clinical trial opportunities open for these patients is an on-going aim. Dr Hall has been an active member of the UK National Cancer Research Institute (NCRI) Ovarian Cancer Study Group since 2010, helping to deliberate and plan the research field for ovarian cancer nationally. She is married with three children and when possible likes to get out in her garden!
Marianne Grønlie Guren <i>Norway</i>	Marianne Grønlie Guren is a Clinical Oncologist, at the Department of Oncology, Oslo University Hospital, Oslo, Norway. Her main clinical expertise is within gastrointestinal cancer, especially within colorectal and anal cancer. She is head of the Norwegian Gastrointestinal Cancer Group – Colorectal, and of the Reference group for the Norwegian Colorectal Cancer Registry, and participates in the K.G. Jebsen Colorectal Cancer Research Centre. Her research focus is within clinical oncology for colorectal and anal cancer, including clinical trials and translational research.
Mark Robinson <i>Wales</i>	Consultant Radiologist in Aneurin Bevan University Health Board (ABHB). I am a General Radiologist with subspecialty interests in Gastro-intestinal Radiology, Uro Radiology and non-vascular intervention. I have been instrumental in establishing the Radiofrequency ablation service in Wales and regularly perform radiofrequency ablation of renal tumours. I have long been interested in improving outcomes for individuals with cancer and have supported this through the following roles in addition

	to supporting research in our Health Board. MDT peer review reviewer Urology and Colorectal. Joint Radiology Lead South Wales Cancer Network: Diagnostic Services Advisory Structure. Radiology Lead, All Wales Colorectal Cancer Advisory Group Lead and RGH lead for bowel screening
Maurice Loughrey <i>Northern Ireland</i>	Dr. Maurice Loughrey MRCP FRCPath MD is a consultant gastrointestinal pathologist in the Royal Victoria Hospital, Belfast, and Honorary Senior Lecturer at Queen's University Belfast. He completed a Doctorate of Medicine in molecular pathology of gastrointestinal neoplasia at the University of Melbourne in 2005. His main expertise is in the pathology of colorectal cancer, precursor polyps and in screening. He is involved in quality assurance of colorectal cancer screening programmes in the UK, regionally and nationally, and is lead author on the Royal College of Pathologists (UK) dataset for reporting colorectal cancer (2014) and on forthcoming UK guidelines for reporting bowel cancer screening pathology (Public Health England). Other interests include molecular pathology epidemiology and digital pathology. Dr. Loughrey provides pathology support for the Northern Ireland Cancer Registry and oversees a research registry of screen-detected colorectal polyps and cancers.
Michael Eden <i>England</i>	Dr. Eden graduated from the University of London and works as a Consultant Pathologist at Cambridge University Hospitals NHS Trust. He also holds positions at the National Cancer Registration and Analysis Service, England as Clinical Lead and Caldicott Guardian and has been involved in Workstream 1, Module 5 of ICBP. He is interested in the role of genomics and IT in delivering pathology services and has international knowledge of cancer registration, staging and tumour classification.
Michael Fung-Kee-Fung <i>Canada</i>	Dr. Michael Fung-Kee-Fung is Professor at the Departments of Obstetrics/ Gynecology and Surgery and cross-appointed to the Telfer School of Management, University of Ottawa. He is currently Head of Surgical Oncology and Chief of Cancer Transformation and Strategy at the Ottawa Regional Cancer Program and The Ottawa Hospital. He has a passionate interest in systems transformation and the role of collaborative methodologies in health innovation including research. He is presently Co-Lead of Health Transformation Exchange Initiative at Telfer. He has pioneered the introduction of the Communities of Practice model in health care as a platform for engagement and innovation harvest, supporting knowledge transfer and systems performance improvements, both at the regional and national levels. In addition he has co-designed and implemented a number of award winning clinical collaboration softwares. Clinically his research focus lies in novel ovarian cancer therapeutics and clinical trials systems redesign. He co-leads the Canadian Cancer Trials Group (CCTG) in gynecology and is a Director of the International Gynecologic Cancer Intergroup (GCIG). He is past chair and current member of Program in Evidence-based Care (PEBC) Gynecologic Cancer, Cancer Care Ontario. He has held a number of leadership positions in Gynecologic Oncology both nationally and provincially and is the recipient of a number of awards for his contributions.
Mick Peake <i>England</i>	Michael D Peake MB, ChB, FRCP. Professor Peake's main current role is as the Clinical Lead for Public Health England's National Cancer Registration and Analysis Service where he oversees the clinical understanding and analysis of UK-wide population data on cancer. He is an Honorary Consultant and Professor of Respiratory Medicine for the University Hospitals of Leicester and has had a major interest in lung cancer and mesothelioma for many years. He has recently stood down as Clinical Lead for the National Lung Cancer Audit in the Royal College of Physicians, where he was Associate Director of the Clinical Effectiveness and Evaluation Unit until 2016. He was National Clinical Lead for Lung Cancer and for NHS Cancer Improvement until the dissolution of the organisation in the NHS reforms. Amongst other roles he is a member of the steering group of the British Thoracic Oncology Group, chair of Mesothelioma UK and a member of the National Advisory Group for Clinical Audit and Enquiries. He has been involved in the development and implementation of national cancer policy since the late 1990s. He has published widely with his major interests being in early diagnosis and improving outcomes for cancer patients by proper service configuration, supported by good clinical outcome data.
Nagappan Kumar <i>Wales</i>	My main interest is in diseases of the liver, gallbladder, bile duct and pancreas. This includes both benign conditions and cancer. I trained in London, Ontario, Canada, Birmingham and Kings College London. I set up the first Liver Unit in Wales in 2002. This is now accredited as the Centre of Excellence in Wales and is the only centre offering liver surgical services to the population of South Wales. We have audited our results regularly and the outcomes are excellent and similar to most national and international centres.
Nancy Baxter <i>Canada</i>	Dr. Nancy Baxter obtained her MD from University of Toronto (UofT) followed by general surgery training and PhD in Clinical Epidemiology at UofT. She completed her fellowship at the Mayo Clinic and is board certified in colon and rectal surgery (2002) and a Fellow of the ASCRS. Currently, she is a practicing colorectal surgeon and the Chief, Division of General Surgery at St. Michael's Hospital. She is a Scientist with the Li Ka Shing Knowledge Institute. Dr. Baxter holds the position of Provincial GI Endoscopy Lead with Cancer Care Ontario. Dr. Baxter is a Professor in the Department of Surgery and Institute of Health Policy, Management and Evaluation at the UofT and a Senior Scientist in the Cancer Theme Group at the Institute for Clinical Evaluative Sciences (ICES). She is a health services researcher interested in the effectiveness of cancer screening, long-term survivorship of cancer survivors and quality of surgical care.
Natalie Coburn <i>Canada</i>	Dr. Coburn is a surgical oncologist at Sunnybrook's Odette Cancer Center with a clinical practice completely devoted to HPB and upper GI cancers. Following training at the University of North Carolina, Brown and Harvard, she completed her fellowship in HPB and upper GI surgical oncology at the University of Toronto. She has been on

	<p>staff at the Odette Cancer Centre since 2004, and has served in many leadership roles including head of the division of general surgery (2012–2015), chief examiner for the Royal College of Physicians and Surgeons of Canada’s surgical oncology fellowship examination (2016–present), and a member of Cancer Care Ontario’s Program in Evidence-Based Care (2005–present). She now holds the Sherif and MaryLou Hanna Chair in Surgical Oncology Research. Dr. Coburn’s research is focused on evaluating and improving the outcomes for patients who have GI tract cancers. She has led several major grants examining patterns of care for treatment of GI cancers within Ontario and the U.S., and has contributed internationally to guideline creation to improve processes of care.</p>
<p>Neil Merrett <i>Australia</i></p>	<p>MB.BS.(Hons) 1980 FRACS 1989 Foundation Professor of Surgery, University of Western Sydney since 2009. He is a Specialist Upper GI Surgeon, Director of Surgery and Head Upper GI Surgery for South Western Sydney Local Health District (SWSLHD) which covers a local population of 1.2 million. His unit is one of the busiest Upper GI Oncology units in Australia and has an extensive interest in the development of databases and protocol driven patient cares and outcomes for malignancy and the development of personalised treatment programmes for patients with Upper GI malignancies. He has had a major contributions to the development of Low volume oncology in NSW including the progressive concentration of UGI oncology in NSW through the NSW Cancer Institute and in collaboration with the Cancer Institute is the Chair of the Working Party developing the recommended diagnostic and treatment algorithms for the treatment of Oesophago-gastric and pancreatic neoplasms as well as the development of patient information resources for patients with these conditions. Amongst his many committee duties, he sits on the SWSLHD Board and Chairs its Healthcare Quality and Safety Committee; Is a member of the NSW State Surgical Taskforce; Is a member of the Surgical Optimisation Working Party for NSW Cancer Institute: Is a Board Member and Member of the Training Committee for Australian and New Zealand Gastro Oesophageal Surgical Association (ANZGOSA) and a Committee Member for the Upper GI section of RACS.</p>
<p>Neville Hacker <i>Australia</i></p>	<p>Professor Neville Hacker AM graduated with First Class Honours from the University of Queensland in 1967. He trained in Obstetrics and Gynaecology at the Royal Women’s Hospital in Brisbane, and went to the University of California, Los Angeles (UCLA) to do a Fellowship in Gynaecological Oncology in 1978. After a 2 year Fellowship, he was appointed to the Faculty and in 1985, he was appointed Director of Gynaecological Oncology at UCLA. In November 1986, he returned to Australia to establish the Gynaecological Cancer Centre at the Royal Hospital for Women. He has been Director of that Centre subsequently, and is a Conjoint Professor of Gynaecological Oncology at the University of New South Wales.</p> <p>Professor Hacker is a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, a Fellow of the Royal College of Obstetricians and Gynaecologists, a Fellow of the American College of Obstetricians and Gynecologists, and a Fellow of the American College of Surgeons.</p> <p>He is a Past Chairman of the Oncology Committee of the RACOG (now RANZCOG), a Past Chairman of the Board of Oncology Examiners for the RACOG, Past President of the International Gynecologic Cancer Society, and a Past President of the (International) Society of Pelvic Surgeons. He has received numerous Awards, including the 2007 Wertheim Award, the 2008 IGCS Award, the inaugural Prof Robert Sutherland Award from the NSW Cancer Institute, and the inaugural Jeanne Ferris Award from the Australian Government and Cancer Australia, both in 2013. He has written over 190 peer-reviewed articles, 44 book chapters, and two books, Hacker and Moore’s Essentials of Obstetrics and Gynecology and Berek and Hacker’s Gynecologic Oncology, both in their 6th Edition.</p>
<p>Nigel Hart <i>Northern Ireland</i></p>	
<p>Patrick Fielding <i>Wales</i></p>	<p>Dr Patrick Fielding graduated from the University of Southampton medical school in 1993 with a first class honours degree in Biomedical Sciences in 1993 and in Medicine in 1994 with honours and distinction in clinical medicine. He worked for 3 years in and around Southampton in medical specialties reaching the level of medical registrar and attaining membership of the Royal College of Physicians.</p> <p>In 1997 he joined the all Wales higher training scheme in Clinical Radiology, based at the University Hospital of Wales in Cardiff but working also at several hospitals in South Wales. He attained Fellowship of the Royal College of Radiologists in 2001 and completed specialist training in clinical radiology in 2003. Following this, Dr. Fielding undertook further specialist training in Nuclear Medicine with a period of specialist training in PET and PET CT imaging at St Thomas Hospital in London in 2004. He completed specialist training in nuclear medicine in 2005.</p> <p>From 2006 to 2010, he worked as a consultant radiologist in Swansea at the now ABMU Health board. During this time, Dr Fielding also worked on a weekly basis at the Cheltenham imaging centre, reporting PET CT studies for many patients in South Wales. Over this period, Dr Fielding also worked with Health Commission Wales (now reformed as WHSSC) in the selection of patient’s for PET CT imaging. During this time, he played an important role in the expansion of funded indications for PET CT imaging 2009.</p>

	<p>Dr Fielding started work at PETIC on the 13th of September 2010, the day on which the full clinical service was commenced. His working week is split between work for the PETIC centre and the Department of Clinical Radiology at the University Hospital of Wales. His particular interests include PET CT imaging in lung cancer and oesophageal cancer and he is a member of the multidisciplinary team for lung cancer and lymphoma. He continues to work with WHSSC and referring clinicians for expansion of clinical indications for PET CT imaging. He is a member of the UK nuclear medicine specialist advisory committee. He is actively involved in a clinical research projects at PETIC, particularly collaborating with upper GI malignancies research team. He serves on the Department of Radiology management team. He currently holds a NISCHR clinical research time fellowship (2014-2017) and is a Bevan Commission Health technology Exemplar (2016). In 2016 he was elected to the fellowship of the Royal College of Physicians.</p>
<p>Paulose George <i>Wales</i></p>	<p>I was appointed to the current post in Feb 2004 with the primary aim of developing Gastroenterology services in Wrexham Maelor, a teaching hospital attached to North Wales Clinical School under University of Cardiff. I worked closely with my colleagues and the hospital management team to lay a stable foundation for the new service. The GI service at Wrexham, with team spirit and a motto of working towards excellence, has evolved into a regional clinical and training centre serving the population of North Wales and neighbouring English counties.</p> <p>I am the clinical lead for endoscopy at Wrexham Maelor Hospital. I have overseen the expansion of GI service at Wrexham and the major developments include regional upper GI cancer centre, JAG accredited national endoscopy training centre and gastroenterology training programme for specialist registrars. Our unit is currently staffed by 5 Medical Gastroenterologists, 5 Surgical Gastroenterologists and 1 GI Radiologist covering different sub speciality areas within gastroenterology.</p> <p>My area of interest is diagnosis and treatment of early malignant and pre malignant lesions in GI tract because I believe that the best way to improve outcome for upper GI cancers is to diagnose and treat early lesions when the tumour burden is the least. I did a sabbatical in 2008 at the world renowned National Cancer Centre Tokyo, an institution with vast experience in diagnosis and treatment of early lesions. I gained experience in advanced diagnostic techniques and endoscopic resection – ESD & EMR – of caners under the guidance of Japanese experts who pioneered these techniques. This resulted in improvement of patient pathway and outcome in our own regional cancer centre. I am also an accredited screening colonoscopist for National bowel screening programme which has been instrumental in improving the outcome of lower GI cancers in UK in the last decade.</p>
<p>Peter Vedsted <i>Denmark</i></p>	<p>Peter Vedsted is Professor of Primary Care at The Research Unit for General Practice, and Professor of Innovative Patient Pathways at Silkeborg Diagnostic Centre, Aarhus University, Denmark. He is the director of a research group for cancer diagnosis investigating the pathway from symptom to treatment of cancer. The group investigates cancer awareness, healthcare seeking, and conducts clinical studies on the role of family medicine in cancer diagnosis. The centre has special focus on health services research and the organisation of healthcare and general practice. Peter Vedsted is involved in many of the Danish initiatives to improve cancer diagnosis and patient pathways and is deeply engaged in how general practice can develop and be supported in providing earlier cancer diagnosis.</p>
<p>Piers Gatenby <i>England</i></p>	<p>Piers Gatenby studied undergraduate medicine at Cambridge University and clinical medicine at Oxford University, where he graduated in 1999. He undertook basic surgical training in South East London before commencing doctoral studies at UCL. He graduated from UCL with his MD in 2007. Subsequently, he undertook higher surgical training with an interest in oesophagogastric surgery in North West London including Imperial College NHS Trust and The Royal Marsden NHS Foundation Trust. He worked as clinical advisor to the NHS Medical Director from 2009-2010 and has undertaken a fellowship in oesophagogastric surgery at Flinders Medical Centre, Adelaide, Australia and including a visit to the Cancer Institute Hospital in Tokyo, Japan.</p>
<p>Rachel Hargest <i>Wales</i></p>	<p>I am a Clinical Senior Lecturer in Colorectal Surgery and a member of the Cardiff China Medical Research Collaborative (CCMRC). My clinical practice is performed mainly at University Hospital of Wales, with day surgery and clinic commitments at Llandough and Velindre hospitals respectively. I run a large, busy colorectal practice with special interests in colorectal and anal cancer, genetic disorders which predispose to colorectal cancer, redo and damage limitation surgery, the “catastrophe abdomen” and intestinal failure and complex proctology including fistulae. I collaborate with other members of CCMRC in studying the mechanisms by which tumours can metastasize (spread) throughout the body. I jointly supervise PhD and MD students, and coordinate clinical placements for visiting overseas post graduate students and doctors.</p>
<p>Richard Adams <i>Wales</i></p>	<p>Richard Adams is Reader and Consultant Clinical Oncologist at Cardiff University and Velindre Cancer Centre. He is the Interim Director of the Wales Cancer Trials Unit. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the National Cancer Research Institute anorectal cancer and CTRad WS2 (UK radiotherapy research) subgroups. He is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD.</p>

	Richard chairs the biomarker development group for the UK phase III FOCUS4 trial in metastatic colorectal cancer and is Chief investigator for the FOCUS4 D trial. He leads on the radiotherapy quality assurance programme for the UK ARISTOTLE, COPERNICUS and TREC trials. He has a role within Wales to engage researchers in translational research and leads work package 3 of the Wales Cancer Research Centre. He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Cancer Care link with Sierra Leone.
Richard Neal <i>England</i>	Richard is Professor of Primary Care Oncology at the Leeds Institute of Health Sciences, Leeds University. Prior to this he was Professor of Primary Care Medicine and Director of the North Wales Centre for Primary Care Research, Bangor University. He has been a Research Training Fellow, Lecturer and Senior Lecturer at the Centre for Research in Primary Care at the University of Leeds previously. Richard's main research interests are in the diagnosis and management of cancers in general practice. He holds various administrative and representative roles including Chair of the (UK) National Cancer Research Institute (NCRI) Primary Care Clinical Studies Group. He is a founding member of Ca-PRI (the International Cancer and Primary Care Research Network). He has won over £5M in externally peer reviewed research and research infrastructure funding in the last five years, and has published 127 peer reviewed papers.
Richard Roope <i>England</i>	Richard Roope is a Portfolio GP working in Primary Care and Cancer Management. He trained at Gonville & Caius College, Cambridge and The Royal London Hospital, qualifying in 1987. Following House Jobs, and the GP Training Scheme in Oxford he joined his current practice. He has been a Primary Care Cancer Lead since 2002. In 2011 he became the CSCCN GP Cancer Lead. In April 2014 he took on the role of RCGP and CRUK Clinical Lead for Cancer. Since July 2015 he has been a Senior Clinical Advisor at Cancer Research UK. He is a member of a number of UK Committees, including the UK National Cancer Advisory Group.
Robert Bleehen <i>Wales</i>	Dr Robert Bleehen MA MB BChir MRCP FRCR graduated from University of Cambridge, England and is a Consultant Radiologist in Cardiff, Wales, specialising in colorectal and gynaecological cancer imaging. He supports the SE Wales gynaecological cancer network MDT, South Wales Cancer Network Gynaecological Advisory Group and Wales Gynaecological Cancer National Specialist Advisory Group. He is active in medical politics through his current elected representative roles on BMA Welsh Consultants Committee and BMA Welsh Council.
Ross Lawrenson <i>New Zealand</i>	Professor Ross Lawrenson (MBBS London, MD London, FRCGP, FFPH FAFPHM) is Professor of Population Health at the University of Waikato, New Zealand. He has a track record of health services research using GP databases and record linkage. He has also been leading research into health inequalities within New Zealand. His recent research includes studies into prostate and breast cancer. He has been Deputy Chair of the New Zealand Guidelines Group, Chair of the National Screening Advisory Board and is Chair of the Primary Care Working group for the Ministry of Health Prostate Taskforce, a member of the New Zealand Cancer Health Information Strategy Governance Board and a Board member of PHARMAC.
Roy Maxwell <i>Northern Ireland</i>	
Scott Fegan <i>Scotland</i>	Scott undertook his undergraduate training at the University of Oxford and St Bartholomew's Hospital Medical College. He began training in Obstetrics & Gynaecology in Glasgow and subsequently was appointed to the South-East Scotland Registrar training programme. He was a Cancer Research UK Clinical Research Fellow from 2004-2007 and was awarded his PhD by the University of Edinburgh. He is a consultant gynaecological oncologist at the Royal Infirmary of Edinburgh and has been involved in the development of the SIGN Guideline concerning ovarian cancer management, and Quality Performance Indicators for gynaecological cancers for Healthcare Improvement Scotland.
Susanna Hill <i>England</i>	Susanna has been a principal in General Practice in North Devon for 29 years. Having obtained the Diploma in Palliative medicine in 1997 she went on to work as the first doctor at the North Devon Hospice supporting the Community Nursing team and Day Care Centre. Susanna was subsequently appointed as a Macmillan GP Facilitator in Cancer and End of Life Care and worked to introduce the Integrated Care Pathway for the Dying, Gold Standards Framework, 'Just in Case', prescribing and other initiatives aimed at improving End of Life Care for patients, initially in North Devon and then with colleagues across the South West Peninsula. Today Susanna still works as a Macmillan GP Facilitator with six colleagues in Devon. She is a Macmillan GP Advisor for Devon and Cornwall leading the Macmillan Primary care team and is the Acute and Emergency Care Clinical Lead for the South West End of Life Network. She is committed to medical training, working for the University of Exeter Medical School as a Community Sub-Dean in North Devon and Associate Dean for Quality and Assessment at the GP School in 'Health Education England – working across the South West'. She is senior partner in her practice in Braunton and still feels excited by the challenges of providing high quality care in the Community and that is an amazing privilege to work as a GP!
Tom Crosby <i>Wales</i>	Tom Crosby is Director of Clinical Systems Transformation at Velindre Cancer Centre and Medical Director of the South Wales Cancer Network. Tom has been based in Velindre Cancer Centre since 2008, and has specialised in lung, breast and gastrointestinal Cancer during that time, currently specialising in upper GI cancer.

	<p>Tom leads in Upper GI Oesophageal Chemo-radiotherapy Research, Service and Development in the UK. He has been Chair of the NCRI Upper GI Chemo-radiotherapy Subgroup, Chief Investigator to the series of UK Multi-centre SCOPE trials (SCOPE1, NeoSCOPE and SCOPE 2) supported by CRUK, run through WCTU), Lead of the Royal College Radiology Site Oriented Network, Oncology Lead for the UK National Oesophago-Gastric Cancer Audit.</p> <p>As clinical lead for the Wales Cancer Network, Tom has established a clinical advisory structure based on Health Board and site specific clinical leads, written a national MDT Charter and clinically led Peer Review of Cancer Services in Wales. Tom is the cancer clinical lead for the Cancer Implementation Group and Chairs the Information Subgroup which oversees the development of information needs and performance measures for the Cancer Delivery Plan. Tom has been an examiner for the Royal College Radiology Part 2 Exam and Chair of the UK Cardiff Part 2 FRCR Course.</p> <p>Tom is currently the clinical lead for the Transformation of Cancer Services Programme in South East Wales. This ambitious and exciting programme will seek to redesign the clinical service model to meet the demands of future care and improve outcomes for patients to match the best of those seen elsewhere in the world.</p>
<p>Wendy Anderson <i>Northern Ireland</i></p>	<p>Wendy Anderson has been a Respiratory Consultant with a clinical interest in Lung Cancer since 2000. She has an active, and published, interest in the use of data to drive change locally, nationally and internationally. She first collected, and presented, comprehensive data on all the lung cancer patients in her trust in 2001, prior to the establishment of LUCADA. She has shared the role of Northern Ireland Lung cancer Lead with Jonathan McAleese since 2013. She is the Divisional Medical Director for Acute and Emergency Medicine in the Northern Health and Social Care Trust. She has historically also published on the subject of Asthma and Allergy.</p>
<p>Winson Cheung <i>Canada</i></p>	<p>Dr. Winson Cheung is an Associate Professor of Medicine at the University of British Columbia and Staff Medical Oncologist at the British Columbia Cancer Agency in Vancouver, specializing in gastrointestinal malignancies and melanoma. He is the past recipient of numerous accolades, including the National Cancer Institute of Canada Dorothy Lamont Award, the Novartis Oncology Young Canadian Investigator Award, the Multinational Association of Supportive Care in Cancer Investigator Award, and several American Society of Clinical Oncology Merit Awards. His primary research interest is health services and outcomes research with the aim to ensure appropriate and equitable access to cancer care and to enhance delivery of cancer therapies to all patients. Recently, he has focused on the important topics of geriatric oncology and survivorship in hopes of understanding how best to manage the growing population of elderly cancer patients as well as survivors. Dr. Winson Cheung publishes extensively in scientific journals and also takes great pride in mentoring young trainees, many of whom have been recognized for research conducted under his supervision. He is also the Chair of the Monitoring and Evaluation Working Group for Colorectal Cancer Screening at the Canadian Partnership Against Cancer where his energy is devoted to the development, validation, and measurement of quality indicators.</p>
<p>Wyn Lewis <i>Wales</i></p>	